Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;59(2):56-63.
doi: 10.3960/jslrt.19013.

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype

Review

Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype

Akira Satou et al. J Clin Exp Hematop. 2019.

Abstract

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs) with a T- or NK-cell phenotype are markedly rare, with only a limited number of cases having been reported thus far. Methotrexate (MTX) is the most common agent used for OIIA-LPD patients, and 43 cases of MTX-associated T-LPDs (MTX T-LPDs) and five cases of MTX-associated NK/T-LPDs (MTX NK-LPDs) have been described. In addition to MTX T-LPDs and MTX NK/T-LPDs, T-LPD and NK/T-LPDs have been reported in patients receiving other immunosuppressive agents such as thiopurines, TNF antagonists, and cyclosporine. Hepatosplenic T-cell lymphoma (HSTL) is specifically associated with iatrogenic immunodeficiency, and 10% of HSTL cases develop in patients receiving thiopurines and/or TNF antagonists for inflammatory bowel disease (IBD). In this review, we focused on MTX T-LPD, MTX NK/T-LPD, and HSTL in patients with IBD. These T- and NK/T-cell associated OIIA-LPDs are the most common in daily medical practice.

Keywords: T or NK/T-cell lymphoma; hepatosplenic T-cell lymphoma; inflammatory bowel disease; methotrexate; other iatrogenic immunodeficiency-associated lymphoproliferative disorder.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: The authors do not have any conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Histological and immunohistochemical features of angioimmunoblastic T-cell lymphoma-type methotrexate-associated T-cell lymphoproliferative disorder (MTX-AITL). MTX-AITL had diffuse and polymorphous infiltration of small- to medium-sized lymphocytes accompanied by the proliferation of high endothelial venules. Small- to medium-sized lymphocytes were characterized by clear cytoplasm (A: HE x 200, B: HE x 400). Immunohistochemically, the tumor cells were positive for PD1 (C: PD1 x 200). Scattered EBV-infected B cells were detected in the background (D: EBER x 200).
Fig. 2
Fig. 2
Histological and immunohistochemical features of EBV+CD8+ cytotoxic T-cell lymphoma (CTL)-type methotrexate-associated T-cell lymphoproliferative disorder. The EBV+CD8+ CTL type was characterized by the infiltration of medium-sized atypical lymphocytes (A: HE x 400). Immunohistochemically, tumor cells were positive for CD8 (B: HE x 400), TIA-1 (C: HE x 400), and EBER (D: EBER x 400).
Fig. 3
Fig. 3
Histological and immunohistochemical features of hepatosplenic T-cell lymphoma. The tumor cells were small to medium in size with pale cytoplasm (A: HE x 400). The liver exhibited predominant sinusoidal infiltration (B: HE x 200). Immunohistochemically, most cases were positive for CD3 (C: CD3 x 400) and TIA-1 (D: TIA-1 x 400). The photographs in Figure 3 were kindly provided by Dr. Ohshima, Kurume University.

Similar articles

Cited by

References

    1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of hematopoietic and lymphoid tissue. Revised 4th ed, Lyon, International Agency for Research on Cancer. 2017; pp. 453-464.
    1. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007; 34: 322-331. - PubMed
    1. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013; 91: 20-28. 10.1111/ejh.12116 - DOI - PubMed
    1. Mariette X, Cazals-Hatem D, Warszawki J, et al. Investigators of the Club Rhumatismes et Inflammation Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99: 3909-3915. 10.1182/blood.V99.11.3909 - DOI - PubMed
    1. Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014; 41: 293-299. 10.3899/jrheum.130270 - DOI - PubMed

MeSH terms